ANITA LAKSON: Open Payments
NPI 1548951676 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$858 in 36 payments from 9 companies in 2025. Trend: 2023 $149 · 2024 $638 · 2025 $858
Food & beverage: $763Education: $95
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $209 |
| Verona Pharma, Inc. | 11 | $161 |
| United Therapeutics Corporation | 1 | $125 |
| GENZYME CORPORATION | 4 | $101 |
| SANOFI-AVENTIS U.S. LLC | 1 | $79 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $70 |
| GlaxoSmithKline, LLC. | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Electromed, Inc. | 3 | $28 |
Products named: DUPIXENT, Ohtuvayre, AIRSUPRA, TYVASO, BREZTRI, OFEV, TRELEGY ELLIPTA, GLASSIA.
Industry payments across NV — which companies pay providers there.
